Ascelia
Malmö, SE · Founded 2000 · 14 employees on LinkedIn · 1 known investors
Ascelia Pharma is a biotech company developing and commercializing drugs for rare, orphan oncology-related conditions with unmet medical needs. Its clinical-stage pipeline includes Orviglance, an oral MRI contrast agent for detecting liver lesions, and Oncoral, an oral chemotherapy tablet for gastric cancer.
Founders & leadership
Investors · 1
Funding
SEC filings, press & company announcements- Undisclosed amountDirected Share IssueApr 2026Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on September 9, 2026 - BioSpacebiospace.com · Aug 2026
Ascelia Pharma: Published FDA letter raises the odds of a more demanding path for Orviglance - Inderesinderes.se · Jul 2026Frequently asked questions
- What does Ascelia do?
- Ascelia Pharma is a biotech company developing and commercializing drugs for rare, orphan oncology-related conditions with unmet medical needs. Its clinical-stage pipeline includes Orviglance, an oral MRI contrast agent for detecting liver lesions, and Oncoral, an oral chemotherapy tablet for gastric cancer.
- Who are Ascelia's investors?
- Ascelia's investors include Sunstone Capital.
- Where is Ascelia headquartered?
- Ascelia is headquartered in Malmö, SE.